Although Merck KGaA's life sciences division is driving growth, thanks to additional business related to the COVID-19 pandemic, the German group's healthcare unit enjoyed a strong third quarter, with sales of the checkpoint inhibitor Bavencio and multiple sclerosis drug Mavenclad comfortably exceeding consensus forecasts.
Group net sales jumped by 11.8% to €5.0bn, driven by what Merck calls the 'big three', namely process solutions, semiconductors...








